Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.

Alexios MatikasSara MargolinMats HellströmHemming JohanssonNils-Olof BengtssonLena KarlssonPer EdlundPer KarlssonElisabet LidbrinkBarbro LinderholmHenrik LindmanPer MalmstromKenneth VillmanTheodoros FoukakisJonas Bergh

Published in: Breast cancer research and treatment (2017)

In this randomized phase II trial, tailored dose adjuvant chemotherapy was feasible, without an increased risk for long-term adverse events after a median follow-up of 10 years.

Keyphrases

open label
placebo controlled
double blind
early breast cancer
phase iii
phase ii
clinical trial
smoking cessation